Page last updated: 2024-09-04

canertinib and Carcinoma, Epidermoid

canertinib has been researched along with Carcinoma, Epidermoid in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J	1
Ako, E; Hirakawa, K; Hori, T; Kubo, N; Ohira, M; Sawada, T; Yamashita, Y; Yamazaki, M	1
de Bock, C; Denny, WA; Ferguson, LR; Gieseg, MA	1

Reviews

1 review(s) available for canertinib and Carcinoma, Epidermoid

Article	Year
[Targeting of epidermal growth factor receptor and applications in ORL cancer]. Bulletin du cancer, 2003, Volume: 90 Spec No Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines	2003

Article

Year

[Targeting of epidermal growth factor receptor and applications in ORL cancer].

Bulletin du cancer, 2003, Volume: 90 Spec No

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines

2003

Other Studies

2 other study(ies) available for canertinib and Carcinoma, Epidermoid

Article	Year
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncology reports, 2007, Volume: 17, Issue:4 Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2007
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anti-cancer drugs, 2001, Volume: 12, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cells, Cultured; Cisplatin; DNA Adducts; DNA Repair; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Fibroblasts; Humans; Luciferases; Mice; Morpholines; Tumor Cells, Cultured	2001

Article

Year

The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.

Oncology reports, 2007, Volume: 17, Issue:4

Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2007

Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.

Anti-cancer drugs, 2001, Volume: 12, Issue:8

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cells, Cultured; Cisplatin; DNA Adducts; DNA Repair; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Fibroblasts; Humans; Luciferases; Mice; Morpholines; Tumor Cells, Cultured

2001